Vanguard Global Advisers
BOLD

Vanguard Global Advisers’s Boundless Bio BOLD Stock Holding History

Vanguard Global Advisers’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-429
Closed -$472 – 3749
2026
Q1 		$472 Buy
+429
New +$502 ﹤0.01% 3661

Other funds holding BOLD

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Global Advisers's BOLD Position: Q2 2026 in Review

Vanguard Global Advisers sold out of Boundless Bio (BOLD) in Q2 2026, closing a stake of 429 shares — an estimated $472 sold.

Vanguard Global Advisers first reported a position in BOLD in Q1 2026 and held it in 1 quarter. The position peaked at $472 in Q1 2026. 34 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

  • Vanguard Global Advisers reported no remaining Boundless Bio position as of Q2 2026 after selling out during the quarter.
  • Vanguard Global Advisers sold 429 Boundless Bio shares in Q2 2026, an estimated $472.
  • Vanguard Global Advisers first reported a position in Boundless Bio in Q1 2026 and held it in 1 quarter.
  • Vanguard Global Advisers's Boundless Bio position peaked at $472 in Q1 2026.
  • 34 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.